ERBB2 and breast cancer: The SOLAR-1 trial randomly assigned 572 patients with pre-treated HR+/HER2–negative advanced BC to receive the oral PIK3CA inhibitor alpelisib plus fulvestrant or fulvestrant plus placebo (54).